Attention Laurel Patients:  Effective, Tues May 28th, the new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707……  Attention  Annapolis Patients: The One Community in Care event will be held on June 8th from 11am-2pm in the Annapolis parking lot.

Trial Protocol ID USOR 22080_D8531C00002_CAMBRIA

Trial Description

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Carol Tweed, M.D.

Disease Types

Sponsor

  • AstraZeneca Fortrea, Inc.